NATCO PHARMA
Quarterly Results Analysis [Sep2024]
NATCO PHARMA Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,371 Cr | ₹1,363 Cr | ₹1,068 Cr | ₹759 Cr | ₹1,031 Cr | ₹1,141 Cr | ₹898 Cr | ₹493 Cr |
Expenses | ₹567 Cr | ₹558 Cr | ₹571 Cr | ₹491 Cr | ₹573 Cr | ₹613 Cr | ₹559 Cr | ₹387 Cr |
Operating Income | ₹804 Cr | ₹805 Cr | ₹497 Cr | ₹268 Cr | ₹458 Cr | ₹528 Cr | ₹339 Cr | ₹106 Cr |
Other Income | ₹64 Cr | ₹48 Cr | ₹42 Cr | ₹37 Cr | ₹29 Cr | ₹20 Cr | ₹29 Cr | ₹21 Cr |
Interest | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr |
Depreciation | ₹46 Cr | ₹44 Cr | ₹56 Cr | ₹44 Cr | ₹44 Cr | ₹44 Cr | ₹41 Cr | ₹42 Cr |
Profit Before Tax | ₹818 Cr | ₹804 Cr | ₹478 Cr | ₹256 Cr | ₹440 Cr | ₹500 Cr | ₹324 Cr | ₹81 Cr |
Profit After Tax | ₹677 Cr | ₹669 Cr | ₹386 Cr | ₹213 Cr | ₹369 Cr | ₹420 Cr | ₹276 Cr | ₹62 Cr |
EPS | ₹37.84 | ₹37.35 | ₹21.58 | ₹11.88 | ₹20.61 | ₹23.48 | ₹15.11 | ₹3.41 |
Industry Peers & Returns | 1W | 1M | 1Y |
NATCO PHARMA | -0.4% | -3.1% | 72.4% |
SUN PHARMACEUTICAL INDUSTRIES | 0.9% | 4.4% | 50% |
CIPLA | 2.1% | 0.2% | 22.8% |
DR REDDYS LABORATORIES | -1.1% | 12.1% | 18.1% |
ZYDUS LIFESCIENCES | 1.8% | 0.9% | 41.3% |
DIVIS LABORATORIES | 4.6% | -1.1% | 55.6% |
MANKIND PHARMA | 0.9% | 13.3% | 45.6% |
TORRENT PHARMACEUTICALS | 1.2% | 2.5% | 48.2% |
LUPIN | 7.6% | 15.1% | 78.8% |
NATCO PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 0.62 % |
Y-o-Y | 32.94 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹1,371 Cr | 0.62 | |
Jun2024 | ₹1,363 Cr | 27.55 | |
Mar2024 | ₹1,068 Cr | 40.83 | |
Dec2023 | ₹759 Cr | -26.45 | |
Sep2023 | ₹1,031 Cr | -9.57 | |
Jun2023 | ₹1,141 Cr | 27.02 | |
Mar2023 | ₹898 Cr | 82.31 | |
Dec2022 | ₹493 Cr | - |
NATCO PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -0.06 % |
Y-o-Y | 75.61 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹804 Cr | -0.06 | |
Jun2024 | ₹805 Cr | 61.83 | |
Mar2024 | ₹497 Cr | 85.49 | |
Dec2023 | ₹268 Cr | -41.46 | |
Sep2023 | ₹458 Cr | -13.26 | |
Jun2023 | ₹528 Cr | 55.71 | |
Mar2023 | ₹339 Cr | 220.21 | |
Dec2022 | ₹106 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -0.68 % |
Y-o-Y | 32.09 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 58.66% | -0.68 | |
Jun2024 | 59.06% | 26.87 | |
Mar2024 | 46.55% | 31.72 | |
Dec2023 | 35.34% | -20.42 | |
Sep2023 | 44.41% | -4.08 | |
Jun2023 | 46.3% | 22.58 | |
Mar2023 | 37.77% | 75.67 | |
Dec2022 | 21.5% | - |
NATCO PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 1.20 % |
Y-o-Y | 83.33 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹677 Cr | 1.20 | |
Jun2024 | ₹669 Cr | 73.05 | |
Mar2024 | ₹386 Cr | 81.62 | |
Dec2023 | ₹213 Cr | -42.36 | |
Sep2023 | ₹369 Cr | -12.21 | |
Jun2023 | ₹420 Cr | 52.39 | |
Mar2023 | ₹276 Cr | 342.70 | |
Dec2022 | ₹62 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 0.57 % |
Y-o-Y | 37.90 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 49.34 % | 0.57 | |
Jun2024 | 49.06 % | 35.67 | |
Mar2024 | 36.16 % | 28.96 | |
Dec2023 | 28.04 % | -21.63 | |
Sep2023 | 35.78 % | -2.90 | |
Jun2023 | 36.85 % | 19.95 | |
Mar2023 | 30.72 % | 142.85 | |
Dec2022 | 12.65 % | - |
NATCO PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 1.31 % |
Y-o-Y | 83.60 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹37.84 | 1.31 | |
Jun2024 | ₹37.35 | 73.08 | |
Mar2024 | ₹21.58 | 81.65 | |
Dec2023 | ₹11.88 | -42.36 | |
Sep2023 | ₹20.61 | -12.22 | |
Jun2023 | ₹23.48 | 55.39 | |
Mar2023 | ₹15.11 | 343.11 | |
Dec2022 | ₹3.41 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD